EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reproductive outcomes after fertility preservation using tamoxifen or letrozole in women with breast cancer: a long-term follow-up

Bo F Paans, Madelon van Wely, Catharina C M Beerendonk, Jan Peter de Bruin, Astrid E P Cantineau, Taghride Dahhan, Nicole F Klijn, Leonie A Louwe, Jesper M J Smeenk, Mariëtte Goddijn, Eva M E Balkenende

F&S Reports · 2026-04 · 7 (2) · 125-133

DOI: 10.1016/j.xfre.2026.01.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift F&S Reports, 2026-04. Verfasst von Bo F Paans und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Reproductive Medicine, Amsterdam University Medical Center, Amsterdam Reproduction and Development, Amsterdam, the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amsterdam UMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate long-term pregnancy outcomes in young women with breast cancer after ovarian stimulation for fertility preservation, with the addition of tamoxifen or letrozole to standard stimulation vs. no addition.

Design

Follow-up study of the STIM-RCT, which was a multicentre randomized open-label trial (NTR4108), and the STIM-cohort study. Subjects: Women, aged 18-43 years, previously diagnosed with breast cancer who opted for fertility preservation through ovarian stimulation. All surviving women were eligible for follow-up (N = 216) and received an online questionnaire; 141 women from the STIM-RCT and 75 from the STIM-cohort. Exposure: Women receiving ovarian stimulation with the addition of tamoxifen, letrozole, or no addition. Main outcome measures: Natural conception, conception through assisted reproductive technology (ART), pregnancy rates, and live birth rates.

Results

Out of 95 STIM-RCT responders, 36 (38%) received the addition of tamoxifen, 32 (34%) received letrozole, and 27 (28%) no addition (mean follow-up 7 years). Forty-four women became pregnant at least once after cancer treatment, and overall 7 women (7%) used their cryopreserved oocytes or embryos. In total, 63 pregnancies followed, of which 48 (76%) were conceived naturally, i.e., unassisted. Compared with standard ovarian stimulation, adding tamoxifen or letrozole resulted in comparable pregnancy rates in women who had at least one pregnancy after cancer treatment (tamoxifen vs. standard relative risk [RR], 0.92; 95% confidence interval [CI], 0.54-1.58; letrozole vs. standard RR, 0.84; 95% CI, 0.48-1.50), and live birth rates thereafter (tamoxifen vs. standard RR, 0.81; 95% CI, 0.54-1.22; letrozole vs. standard RR, 0.82; 95% CI, 0.53-1.26). In the STIM-cohort, 20 women became pregnant at least once, leading to a total of 30 pregnancies, of which 90% were conceived naturally. One woman used her cryopreserved embryos.

Conclusion

After 7 years of follow-up, most women conceived naturally after cancer treatment, and 8 women used their cryopreserved oocytes or embryos. We found no evidence for a difference in pregnancy rates when adding tamoxifen or letrozole to standard ovarian stimulation compared with no addition.

Schlagwörter

Stichwörter der Autor:innen

Breast carcinomaletrozoleovarian stimulationpregnancytamoxifen

Autor:innen und Institutionen

  • Center for Reproductive Medicine, Amsterdam University Medical Center, Amsterdam Reproduction and Development, Amsterdam, the Netherlands.
  • Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, Den Bosch, the Netherlands.
  • University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Reproductive Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Gynaecology, Leiden University Medical Centre, Leiden, the Netherlands.

Förderung

  • Amsterdam UMC

Zitieren

APA

Paans, B. F., van Wely, M., Beerendonk, C. C. M., de Bruin, J. P., Cantineau, A. E. P., Dahhan, T., Klijn, N. F., Louwe, L. A., Smeenk, J. M. J., Goddijn, M., & Balkenende, E. M. E. (2026). Reproductive outcomes after fertility preservation using tamoxifen or letrozole in women with breast cancer: a long-term follow-up. F&S Reports, 7(2), 125-133. https://doi.org/10.1016/j.xfre.2026.01.006

Vancouver

Paans BF, van Wely M, Beerendonk CCM, de Bruin JP, Cantineau AEP, Dahhan T, et al. Reproductive outcomes after fertility preservation using tamoxifen or letrozole in women with breast cancer: a long-term follow-up. F&S Reports. 2026;7(2):125-133. doi:10.1016/j.xfre.2026.01.006

BibTeX
@article{Paans2026,
  author = {Paans, Bo F and van Wely, Madelon and Beerendonk, Catharina C M and de Bruin, Jan Peter and Cantineau, Astrid E P and Dahhan, Taghride and Klijn, Nicole F and Louwe, Leonie A and Smeenk, Jesper M J and Goddijn, Mariëtte and Balkenende, Eva M E},
  title = {Reproductive outcomes after fertility preservation using tamoxifen or letrozole in women with breast cancer: a long-term follow-up},
  journal = {F&S Reports},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {125--133},
  doi = {10.1016/j.xfre.2026.01.006}
}
Kostenlos starten →